Gabriela Hernández-Martínez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gabriela Hernández-Martínez has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Miguel Ángel Ares
Unidad de Investigación Médica en Enfermedades Infecciosas y Parasitarias, Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City 06720, Mexico
3 shared publications - Roberto Rosales-Reyes
Unidad de Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México
3 shared publications - Verónica Roxana Flores-Vega
Unidad de Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México
3 shared publications - José Luis Lezana-Fernández
Hospital Infantil de México Federico Gómez. Ciudad de México, México
2 shared publications - Miguel Cocotl-Yañez
Departamento de Microbiologia y Parasitologia, Facultad de Medicina, Universidad Nacional Autonoma de Mexico, Ciudad de Mexico, Mexico
2 shared publications - Nilton Lincopan
Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, Brazil
2 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Universidad Nacional Autonoma de Mexico in Revista de la Facultad de Medicina
- Vol. 69 (5)
Fibrosis quística: diagnóstico, complicaciones respiratorias y tratamiento
- 21 October 2026
- Published by Universidad Nacional Autonoma de Mexico in Revista de la Facultad de Medicina
- Vol. 69 (5)
Open AccessFibrosis quística: diagnóstico, complicaciones respiratorias y tratamiento
- Top Cited PapersOpen Access
- 19 March 2026
- Published by American Society for Microbiology in Journal of Bacteriology
- Vol. 208 (3) , e0047125
Contribution of two-component regulatory systems to the acute-to-chronic infection transition of Pseudomonas aeruginosa in cystic fibrosis
Cystic fibrosis (CF) is a life-threatening genetic disorder that causes severe dysfunction in the lungs, digestive system, and other organs. Chronic respiratory infections are a significant cause of morbidity and mortality among CF-related complications. Pseudomonas aeruginosa is an opportunistic bacterial pathogen and a predominant colonizer of the CF lung. It drives a progressive decline in pulmonary function. This pathogen shows remarkable adaptability. It can establish both acute and chronic infections despite the host’s immune defenses and antimicrobial treatments. P. aeruginosa expresses a diverse set of virulence factors, including adhesins, proteases, exotoxins, siderophores, secretion systems, and exopolysaccharides. These factors facilitate host colonization, immune evasion, and disease progression. The transition from acute to chronic infection is mediated by bacterial sensing of environmental signals. These signals dynamically modulate the expression of virulence factors. Also, the hostile conditions within the CF lung drive the acquisition and accumulation of adaptive mutations in the bacterial genome. These genetic modifications often impair the efficiency of DNA repair mechanisms, leading to a hypermutable phenotype. This accelerates bacterial evolution. As a result, acute-phase virulence factors are downregulated, while antimicrobial resistance and biofilm formation increase. This contributes to persistent and refractory infections. In this review, we examine the crucial roles of two-component regulatory systems. These systems fine-tune gene expression, enhance bacterial survival, and regulate the shift from acute to chronic infection. Understanding these adaptive mechanisms is essential for developing novel therapeutic strategies to combat this highly resilient pathogen.
- 19 March 2026
- Published by American Society for Microbiology in Journal of Bacteriology
- Vol. 208 (3) , e0047125
Top Cited PapersOpen AccessContribution of two-component regulatory systems to the acute-to-chronic infection transition of Pseudomonas aeruginosa in cystic fibrosis
Cystic fibrosis (CF) is a life-threatening genetic disorder that causes severe dysfunction in the lungs, digestive system, and other organs. Chronic respiratory infections are a significant cause of morbidity and mortality among CF-related complications. Pseudomonas aeruginosa is an opportunistic bacterial pathogen and a predominant colonizer of the CF lung. It drives a progressive decline in pulmonary function. This pathogen shows remarkable adaptability. It can establish both acute and chronic infections despite the host’s immune defenses and antimicrobial treatments. P. aeruginosa expresses a diverse set of virulence factors, including adhesins, proteases, exotoxins, siderophores, secretion systems, and exopolysaccharides. These factors facilitate host colonization, immune evasion, and disease progression. The transition from acute to chronic infection is mediated by bacterial sensing of environmental signals. These signals dynamically modulate the expression of virulence factors. Also, the hostile conditions within the CF lung drive the acquisition and accumulation of adaptive mutations in the bacterial genome. These genetic modifications often impair the efficiency of DNA repair mechanisms, leading to a hypermutable phenotype. This accelerates bacterial evolution. As a result, acute-phase virulence factors are downregulated, while antimicrobial resistance and biofilm formation increase. This contributes to persistent and refractory infections. In this review, we examine the crucial roles of two-component regulatory systems. These systems fine-tune gene expression, enhance bacterial survival, and regulate the shift from acute to chronic infection. Understanding these adaptive mechanisms is essential for developing novel therapeutic strategies to combat this highly resilient pathogen.
- Open Access
- 31 October 2025
- Published by Taylor & Francis in Virulence
- Vol. 16 (1) , 2580097
Colistin-induced transition from non-mucoid to mucoid phenotype in resistant Pseudomonas aeruginosa ST3351
Pseudomonas aeruginosa is an opportunistic pathogen frequently infecting the lower airways of individuals with cystic fibrosis (iwCF). We investigated colistin (CST) resistance mechanisms in P. aeruginosa ST3351 (Psa-ST3351) and their impact on bacterial virulence. Psa-ST3351, a novel CST-resistant sequence type, was isolated from a child with CF. We demonstrate that CST resistance in Psa-ST3351 depends on the addition of 4-amino-4-deoxy-L-arabinose to lipid A. Moreover, exposure to CST induced a non-mucoid-to-mucoid phenotypic switch characterized by enhanced swarming motility, decreased susceptibility to aminoglycosides, impaired ExoS secretion via the type-III secretion system, and increased bacterial competition, all hallmarks of a chronic infection phenotype. CST-treated Psa-ST3351 also exhibited reduced phagocytosis by macrophages, despite the induction of pro-inflammatory cytokines remaining unaffected, and enhanced the pathogenicity in a mouse pneumonia model. These findings suggest that CST-induced mucoid conversion in CST-resistant Psa-ST3351 May contribute to disease progression in iwCF, particularly when CST resistance and mucoid conversion remain undetected during CST nebulized therapy.
- 31 October 2025
- Published by Taylor & Francis in Virulence
- Vol. 16 (1) , 2580097
Open AccessColistin-induced transition from non-mucoid to mucoid phenotype in resistant Pseudomonas aeruginosa ST3351
Pseudomonas aeruginosa is an opportunistic pathogen frequently infecting the lower airways of individuals with cystic fibrosis (iwCF). We investigated colistin (CST) resistance mechanisms in P. aeruginosa ST3351 (Psa-ST3351) and their impact on bacterial virulence. Psa-ST3351, a novel CST-resistant sequence type, was isolated from a child with CF. We demonstrate that CST resistance in Psa-ST3351 depends on the addition of 4-amino-4-deoxy-L-arabinose to lipid A. Moreover, exposure to CST induced a non-mucoid-to-mucoid phenotypic switch characterized by enhanced swarming motility, decreased susceptibility to aminoglycosides, impaired ExoS secretion via the type-III secretion system, and increased bacterial competition, all hallmarks of a chronic infection phenotype. CST-treated Psa-ST3351 also exhibited reduced phagocytosis by macrophages, despite the induction of pro-inflammatory cytokines remaining unaffected, and enhanced the pathogenicity in a mouse pneumonia model. These findings suggest that CST-induced mucoid conversion in CST-resistant Psa-ST3351 May contribute to disease progression in iwCF, particularly when CST resistance and mucoid conversion remain undetected during CST nebulized therapy.